Lung Cancer Dispatch
Follow
Find tag "GALAXY-2 trial"
3.7K views | +0 today
Lung Cancer Dispatch
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Scooped by Cancer Commons
Scoop.it!

Synta Announces Results from Final Analysis of the GALAXY-1 Trial of Ganetespib in NSCLC

Synta Announces Results from Final Analysis of the GALAXY-1 Trial of Ganetespib in NSCLC | Lung Cancer Dispatch | Scoop.it

"Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced final results from the GALAXY-1 trial, a global, randomized, multi-center study designed to identify the patients with advanced non-small cell lung cancer (NSCLC) with adenocarcinoma histology most likely to benefit from second-line treatment with the Company’s lead drug candidate, the Hsp90 inhibitor ganetespib, in combination with docetaxel versus docetaxel alone. Ganetespib is a next-generation inhibitor of the chaperone protein Hsp90, which is critical for the activation and stability of numerous proteins that drive cancer growth and proliferation. Ganetespib has been studied in over 1000 patients to date."


Editor's note: This story is about clinical trials designed to test the drug ganetespib in people with non-small cell lung cancer (NSCLC). The drug manufacturer (Synta) recently reported updated results for one of the trials, GALAXY-1. The results confirm that the researchers were able to identify patients who were most likely to benefit from a treatment that combines ganetespib with the chemotherapy drug docetaxel.

Cancer Commons's insight:

Synta  |  May 8, 2014

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

FDA Puts Lung Cancer Drug Ganetespib on Fast Track

FDA Puts Lung Cancer Drug Ganetespib on Fast Track | Lung Cancer Dispatch | Scoop.it

Ganetespib, a potential new treatment for non-small cell lung cancer (NSCLC), has been granted Fast Track status by the U.S. Food and Drug Administration (FDA). Fast Track status, reserved for drugs aimed at serious conditions with unmet treatment needs, provides for closer FDA guidance during the drug development process and quicker review for approval. Two clinical trials, GALAXY-1 and GALAXY-2, are currently examining the use of ganetespib in combination with the chemotherapy agent Taxotere (docetaxel) for treating advanced lung adenocarcinoma, a type of NSCLC. Ganetespib acts by blocking Hsp90, a protein that facilitates several components of tumor development and spread.

Cancer Commons's insight:

MarketWatch | Sep 12, 2013

more...
No comment yet.